Insmed第二季度每股收益低于市场预期，营收增长17%，但StockNews下调了评级。 Insmed Q2 EPS misses consensus estimates, revenue increases 17%, but StockNews downgrades rating.
Insmed报告说,该公司的Q2 EPS为1.94美元,没有达成共识的估计数(0.72美元),但该公司的收入增加了17%,达到90.34万加元。 Insmed reported Q2 EPS of ($1.94), missing consensus estimates by ($0.72), but the company's revenue increased 17% to $90.34M. 尽管摩根斯坦利这样的分析家提高了价格目标并保持了购买评级, StockNews.com 将Insmed降为销售评级。 Despite analysts like Morgan Stanley raising price targets and maintaining buy ratings, StockNews.com downgraded Insmed to a sell rating. 首席执行官威廉·刘易斯（William Lewis）和首席财务官萨拉·邦斯坦（Sara Bonstein）已出售股票，而Vanguard Group和Principal Financial Group则增持了股票。 CEO William Lewis and CFO Sara Bonstein have sold shares, while Vanguard Group and Principal Financial Group increased their holdings.